Levofloxacin vs. azithromycin pharmacodynamic activity against S. pneumoniae and H. influenzae with decreased susceptibility to amoxicillin/clavulanic acid

Journal of Chemotherapy

Volumn 19, Issue 6, 2007, Pages 670-672

  Alou, L ^a   Aguilar, Lorenzo ^a   Sevillano, D ^c   Gimenez M J ^a   Gonzalez N ^a   Echeverria O ^a   Torrico, M ^a   Martin J E ^b   Valdes L ^b   Prieto, J ^a  

^a SCHOOL OF MEDICINE   (Spain)

^b GLAXOSMITHKLINE   (Spain)

^c NONE

Author keywords

Azithromycin; BLNAR; H. influenzae; Levofloxacin; Pharmacodynamic simulation; S. pneumoniae

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; BETA LACTAMASE; LEVOFLOXACIN;

ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; SIMULATION; STREPTOCOCCUS PNEUMONIAE;

EID: 38949145277     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2007.19.6.670     Document Type: Article

References (11)

1. Pérez-Trallero E, García-de-la-Fuente C, García-Rey C et al. Geographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain. Antimicrob Agents Chemother 2005; 49: 1965-1972.
2. Perez-Trallero E, Marimon JM, Gonzalez A, García-Rey C, Aguilar L. Genetic relatedness of recently collected Spanish respiratory tract Streptococcus pneumoniae isolates with reduced susceptibility to amoxicillin. Antimicrob Agents Chemother 2003; 47: 3637-3639.
3. Garcia-de-Lomas J, Lerma M, Cebrian L et al. Cefditoren activity against H. influenzae with different ampicillin susceptibility phenotypes. In: Program and abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2006, Abstract E-111.
4. MacGowan AP, Wise R. Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. J Antimicrob Chemother 2001; 48: 17-28.
5. th edition. NCCLS M7-A6. NCCLS, Wayne, Pa., 2003.
6. Alou L, Gimenez MJ, Sevillano D et al. A pharmacodynamic approach to antimicrobial activity in serum and epithelial lining fluid against in vivo-selected Streptococcus pneumoniae mutants and association with clinical failure in pneumonia. J Antimicrob Chemother 2006; 58:349-358.
7. rd generation oral cephalosporin (cefpodoxime versus cefditoren) against Streptococcus pneumoniae. J Chemother 2007; 2007; 19 (3): 288-294.
8. Amsden GW. Erythromycin, clarithromycin, and azithromycin: are the differences real? Clin Ther 1996; 18: 56-72.
9. Sevillano D, Alou L, Aguilar L, Echevarria O, Gimenez MJ, Prieto J. Azithromycin iv pharmacodynamic parameters predicting Streptococcus pneumoniae killing in epithelial lining fluid versus serum: an in vitro pharmacodynamic simulation. J Antimicrob Chemother 2006;57:1128-1133.
10. Lonks JR, Garau J, Gomez L et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002;35:556-564.
11. Perez-Trallero E, Marimon JM, Gonzalez A, Ercibengoa M, Larruskain J. In vivo development of high-level fluoroquinolone resistance in Streptococcus pneumoniae in chronic obstructive pulmonary disease. Clin Infect Dis 2005;41:560-564.